Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses...
23 KB (1,833 words) - 20:37, 1 November 2024
medications, such as the CD20 antibody rituximab and the CD19 CAR T cell tisagenlecleucel. The experimental drug TGN1412—also known as Theralizumab—caused extremely...
24 KB (2,551 words) - 01:16, 25 June 2024
to the FDA's first two approvals of CAR T cells in 2017, those for tisagenlecleucel (Kymriah), marketed by Novartis originally for B-cell precursor acute...
85 KB (8,798 words) - 21:08, 9 December 2024
as a recent advance in treating refractory and relapsed DLBCL, NOS (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel). Chimeric antigen...
69 KB (8,143 words) - 23:37, 9 November 2024
of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel". Journal of Hematology & Oncology. 11 (1): 35. doi:10.1186/s13045-018-0571-y...
25 KB (2,786 words) - 02:05, 24 June 2024
high risk) Kisqali (ribociclib) Breast Cancer 1,231 2022 Kymriah (tisagenlecleucel) Acute lymphoblastic leukemia Lamisil (terbinafine) Fungal infections...
151 KB (12,488 words) - 15:55, 30 November 2024
approved, such as alipogene tiparvovec (2012), Strimvelis (2016), tisagenlecleucel (2017), voretigene neparvovec (2017), patisiran (2018), onasemnogene...
179 KB (18,426 words) - 01:50, 21 November 2024
treatment for melanoma in patients who have recurring skin lesions Tisagenlecleucel (Kymriah): treatment for B cell lymphoblastic leukemia Valoctocogene...
11 KB (834 words) - 06:28, 10 November 2024
found in children younger than 15 and elders older than 55. In 2017, tisagenlecleucel (Kymriah™), the first CAR-T cell therapy approved by the FDA, became...
11 KB (1,227 words) - 23:23, 20 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
26 KB (2,420 words) - 17:03, 13 November 2024
can initiate a cytotoxic response.[medical citation needed] In 2017, tisagenlecleucel was approved by the FDA as a CAR-T therapy for people with acute B-cell...
80 KB (7,802 words) - 18:17, 18 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
31 KB (2,913 words) - 23:49, 9 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
20 KB (1,870 words) - 19:10, 15 December 2024
Memorial Sloan Kettering Cancer Center. Retrieved October 15, 2019. "Tisagenlecleucel (Kymriah) Approved to Treat Some Lymphomas". National Cancer Institute...
43 KB (3,682 words) - 00:35, 1 November 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
19 KB (1,757 words) - 09:15, 29 October 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
13 KB (869 words) - 05:58, 10 June 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
61 KB (6,093 words) - 19:43, 7 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
17 KB (1,747 words) - 19:53, 17 March 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
13 KB (1,449 words) - 12:45, 21 August 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
19 KB (1,669 words) - 22:21, 6 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
41 KB (3,764 words) - 13:54, 13 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
33 KB (2,959 words) - 02:09, 16 July 2024
lymphoma with two failed systemic treatments), axicabtagene ciloleucel, tisagenlecleucel (for large B-cell lymphoma), and brexucabtagene autoleucel (for mantle...
67 KB (6,603 words) - 19:22, 22 November 2024
for years. His work led to the development and commercialization of tisagenlecleucel, the first FDA-approved cell therapy. 1978 - Alpha Omega Alpha Medical...
12 KB (1,150 words) - 12:11, 21 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
57 KB (6,281 words) - 21:40, 24 November 2024
(INN) tirofiban (INN) tiropramide (INN) tirzepatide (INN) Tis-U-Sol tisagenlecleucel (USAN, INN) Tiseb Tisit tislelizumab (INN) tisocalcitate (USAN) tisocromide...
12 KB (519 words) - 05:21, 24 November 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
30 KB (2,807 words) - 07:32, 30 November 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
25 KB (2,190 words) - 16:38, 21 November 2024
infuse the resulting CAR-T cells into patients to attack their tumors. Tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR-T) therapy, was approved...
92 KB (12,517 words) - 09:00, 20 December 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
27 KB (2,575 words) - 07:01, 24 November 2024